Skip to main content
TipRanks
Go Ultimate75% OFF

Wakamoto Pharmaceutical Co., Ltd. (4512) AI Stock Analysis

0 Followers
JP:4512

Wakamoto Pharmaceutical Co., Ltd.

(TSE/TYO:4512)

Select Model
Rating:39Underperform
Price Target:JPY 272.00â–¼(-5.88% Downside)
Action:downgraded
Date:11/19/26

Wakamoto Pharmaceutical scores poorly, driven primarily by persistently negative operating and free cash flow and very thin profitability, which raise concerns about earnings quality and the sustainability of the business model without external funding. A fortress-like, near debt-free balance sheet and a forecast 27.2% revenue rebound provide some cushion and a potential turnaround signal, but chronically low returns on equity show weak capital efficiency. Technicals add little support, with the shares trading below most key moving averages and a negative MACD. Valuation compounds the risk, as a P/E near 56 is difficult to justify on current earnings power, with only a 1.2% dividend yield as offset.

Positive Factors
Revenue and earnings recoveryRevenue growth of about 27% alongside positive EBIT and net income in the latest annual period indicates a meaningful earnings recovery. If sustained, stronger demand can improve operating scale and provide a broader base for investment across the company’s OTC and healthcare portfolio.
Negative Factors
Persistent weak cash generationOperating cash flow and free cash flow were negative for three consecutive years from 2024 through 2026, with latest FCF around -Â¥1.05B. Persistent cash conversion weakness can undermine earnings quality, consume reserves, and limit internally funded investment despite the low-debt balance sheet.

Wakamoto Pharmaceutical Co., Ltd. (4512) vs. iShares MSCI Japan ETF (EWJ)

-20%-10%0%10%20%30%40%JP:4512+5.59%EWJ+11.78%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 9.82B
Dividend Yield
1.21%
Average Volume (3M)
38.07K
Price to Earnings (P/E)
54.1
Beta (1Y)
0.40
Revenue Growth
23.41%
EPS Growth
149.71%
Country
Japan
Employees
303
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Wakamoto Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely re...

Wakamoto Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

Financials are weak overall. Cash flow is the biggest problem (score 18): operating cash flow has been negative in three of the last four periods (-¥592M in FY2025, -¥487M forecast FY2026) and free cash flow is deeply negative near -¥1.05B, meaning reported profits are not backed by cash. The income statement (score 32) shows an encouraging 27.2% revenue rebound to ¥9.9B forecast for FY2026, but margins are razor-thin (2.3% net, 2.6% EBIT) after operating losses in three of five years and a ¥602M net loss in FY2021. The balance sheet (score 68) is the clear bright spot, with a near debt-free structure (debt/equity under 3.4%) and ~¥12B of equity providing downside protection — though chronically low ROE (-5.3% to 2.1%) shows that capital is poorly utilized.

Income Statement

32Negative

Balance Sheet

68Positive

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue7.98B9.91B7.79B7.74B8.66B8.38B
Gross Profit3.75B4.73B3.62B3.54B4.11B4.36B
EBITDA397.01M701.22M438.68M570.97M657.90M755.52M
Net Income-177.67M227.22M64.44M108.96M138.26M238.54M
Balance Sheet
Total Assets15.25B16.50B15.00B15.42B15.71B14.95B
Cash, Cash Equivalents and Short-Term Investments3.56B2.01B2.95B3.66B3.88B3.23B
Total Debt100.00M400.00M100.00M130.73M529.00K2.65M
Total Liabilities3.55B4.49B3.39B3.39B3.80B3.47B
Stockholders Equity11.70B12.01B11.61B12.03B11.91B11.48B
Cash Flow
Free Cash Flow0-1.05B-1.04B-663.02M420.76M-28.97M
Operating Cash Flow0-486.91M-592.45M-107.34M631.92M339.17M
Investing Cash Flow0-657.56M-13.50M-2.35M17.13M50.57M
Financing Cash Flow0195.88M-103.94M-104.99M-1.61M-1.62M

Wakamoto Pharmaceutical Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price289.00

Price Trends

50DMA296.26Negative
100DMA287.64Positive
200DMA302.50Negative

Market Momentum

MACD-2.69Positive
RSI45.41Neutral
STOCH78.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4512, the sentiment is Negative. The current price of 289.00 is below the 20-day moving average (MA) of 293.35, below the 50-day MA of 296.26, and below the 200-day MA of 302.50, indicating a bearish trend. The MACD of -2.69 indicates Positive momentum. The RSI at 45.41 is Neutral, neither overbought nor oversold. The STOCH value of 78.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4512.

Wakamoto Pharmaceutical Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4512 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4574JP:457469NeutralJPY 12.72B29.84―1.30%13.72%-50.46%
JP:4524JP:452468NeutralJPY 8.99B10.27―2.95%-0.47%50.82%
JP:4577JP:457767NeutralJPY 37.71B11.98―3.06%-2.83%65.69%
JP:4538JP:453863NeutralJPY 19.04B8.28―4.15%2.29%―
JP:2929JP:292957NeutralJPY 15.50B7.54―4.67%-3.12%406.78%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4512JP:451239UnderperformJPY 10.03B54.14―1.21%23.41%149.71%

* Healthcare Sector Average

Performance Comparison

-20%0%20%JP:4512JP:2929JP:4524JP:4538JP:4574JP:4577Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4512 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4512Wakamoto Pharmaceutical Co., Ltd.289.0015.315.59%
JP:2929Pharma Foods International Co., Ltd.535.00-237.43-30.74%
JP:4524Morishita Jintan Co., Ltd.2204.00111.045.31%
JP:4538Fuso Pharmaceutical Industries,Ltd.2170.0060.422.86%
JP:4574Taiko Pharmaceutical Co., Ltd.254.00-39.00-13.31%
JP:4577Daito Pharmaceutical Co., Ltd.1307.0077.986.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 19, 2026